Financial Wire

市場動向:三菱商事がベトナムの石炭火力発電所で操業を開始

-- 日経アジアは火曜日、関係者の話として、三菱商事(東証:8058)がベトナムに建設した新たな石炭火力発電所で本格的な操業を開始したと報じた。この発電所はインドネシアやオーストラリアなどの近隣諸国から石炭を調達する予定だ。 同紙によると、この取り組みは、急速な経済成長の中で安定した電力供給を確保しつつ、ベトナムが中東からのエネルギー輸入への依存度を低減するのに役立つという。 同紙によると、土曜日に行われたブンアンII発電所の開所式で、ベトナムのグエン・ホアン・ロン副大臣は、このプロジェクトが国家のエネルギー安全保障と経済成長にとって重要であると述べた。 三菱商事の船山哲氏は、アジアのエネルギー安全保障の自立の重要性を強調したと報じられている。 同紙は、ブンアンII発電所は25年間の契約に基づき、操業を支えるためにインドネシアとオーストラリアから年間360万トンから400万トンの石炭を調達すると付け加えた。 (マーケットチャッターのニュースは、世界中の市場専門家との会話から得られた情報に基づいています。この情報は信頼できる情報源に基づいていると考えられますが、噂や憶測が含まれている可能性があります。正確性は保証されません。)

Related Articles

Asia

Huadian New Energy 2025 Profit Down 18%, Revenue Up 15%

Huadian New Energy (SHA:600930) posted 2025 attributable net profit of 7.26 billion yuan, down 18% from 8.83 billion yuan the previous year.Earnings per share slipped to 0.18 yuan from 0.24 yuan, according to a filing with the Shanghai bourse.Operating revenue rose 15% year over year to 39.0 billion yuan from 34.0 billion yuan.Shares of the power company were down 1% in recent trade.

$SHA:600930
Asia

National Storage REIT Says New South Wales Court Approves Brookfield, GIC Takeover Scheme

National Storage REIT (ASX:NSR) confirmed that the Supreme Court of New South Wales has approved the share scheme of arrangement and granted judicial advice for the trust scheme, enabling a Brookfield Funds and GIC-led consortium to proceed with the acquisition of all the company stapled securities, according to a Tuesday Australian bourse filing.The schemes are now legally effective following lodgment with the Australian Securities and Investments Commission, and the company's securities are expected to be suspended from trading at the close of trading on Tuesday, per the filing.The scheme record date is April 29, with implementation scheduled for May 8, when security holders will receive the scheme consideration, the filing added.

$ASX:NSR
Asia

Starpharma Says US FDA Supports First-in-Human Study of Cancer Radiotherapy Candidate; Shares Gain 7%

Starpharma Holdings (ASX:SPL) has received positive feedback from the US Food and Drug Administration (FDA) on the proposed design of its first-in-human phase 1 clinical study of the DEP HER2 radiotherapy candidate, according to a Tuesday filing with the Australian bourse.The company is developing the candidate to treat certain gastric/gastro-oesophageal junction cancers and other advanced cancers in patients who have previously received targeted therapy.The US FDA feedback supports plans to launch the phase one study, which is on track to begin in the second half of the year.The FDA also confirmed that the radiotherapy candidate is targeting a population with a significant unmet medical need, indicating the potential for a fast-track designation or other accelerated development pathways, Starpharma said.The company's shares were 7% higher in recent Tuesday trade.

$ASX:SPL